Zacks: Brokerages Anticipate Apricus Biosciences Inc (APRI) Will Post Earnings of -$0.13 Per Share

Wall Street analysts predict that Apricus Biosciences Inc (NASDAQ:APRI) will post ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Apricus Biosciences’ earnings. Apricus Biosciences posted earnings per share of ($0.04) during the same quarter last year, which indicates a negative year over year growth rate of 225%. The business is expected to report its next earnings results on Monday, March 12th.

On average, analysts expect that Apricus Biosciences will report full year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.92) to ($0.28). For the next financial year, analysts expect that the company will report earnings of $1.28 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Apricus Biosciences.

Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same period in the previous year, the company posted ($0.19) earnings per share.

Several research firms have weighed in on APRI. ValuEngine upgraded Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research cut Apricus Biosciences from a “buy” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $4.50 target price on shares of Apricus Biosciences in a research note on Friday, November 3rd.

A hedge fund recently bought a new stake in Apricus Biosciences stock. Healthcare Value Capital LLC purchased a new stake in Apricus Biosciences Inc (NASDAQ:APRI) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences comprises approximately 0.6% of Healthcare Value Capital LLC’s portfolio, making the stock its 8th largest holding. Healthcare Value Capital LLC owned 0.66% of Apricus Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 24.01% of the company’s stock.

Shares of Apricus Biosciences (APRI) opened at $2.25 on Friday. Apricus Biosciences has a 12 month low of $0.86 and a 12 month high of $3.49. The firm has a market capitalization of $36.21, a price-to-earnings ratio of 3.88 and a beta of 0.38.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/09/zacks-brokerages-anticipate-apricus-biosciences-inc-apri-will-post-earnings-of-0-13-per-share.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply